| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 40.56% | 37.82% | 36.12% | 59.28% | 78.29% | 78.70% | 56.63% | 49.90% | 54.35% | 63.22% | 47.07% | 26.76% |
| Operating Margin | -28.23% | -26.08% | -67.61% | 28.84% | 68.10% | 68.80% | -1.32% | -23.75% | -18.59% | 5.02% | -52.34% | -77.46% |
| EBITDA Margin | -20.76% | -17.28% | -58.57% | 34.12% | 69.21% | 69.51% | 5.16% | -13.62% | -9.36% | 11.42% | -46.33% | -62.13% |
| Net Margin | -18.75% | -15.07% | -58.03% | 23.17% | 51.12% | 50.82% | -1.26% | -26.26% | -13.40% | -29.26% | -86.82% | -335.13% |
| Current Ratio | 6.48 | 4.85 | 6.96 | 7.13 | 5.81 | 4.02 | 9.96 | 14.44 | 10.98 | 7.88 | 4.27 | — |
| Quick Ratio | 6.48 | 4.85 | 6.96 | 7.13 | 5.81 | 4.02 | 9.96 | 14.44 | 10.98 | 7.88 | 4.27 | — |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -5.47% | -3.78% | -14.81% | 11.29% | 43.52% | 37.64% | -0.50% | -10.96% | -4.63% | -9.81% | -161.56% | — |
| ROA | -4.99% | -3.50% | -13.59% | 10.35% | 39.68% | 30.60% | -0.46% | -10.40% | -4.39% | -9.21% | -142.56% | — |
| Asset Turnover | 0.27 | 0.23 | 0.23 | 0.45 | 0.78 | 0.60 | 0.37 | 0.40 | 0.33 | 0.31 | 1.64 | — |
| Book Value / Share | 35.96 | 37.35 | 38.05 | 41.01 | 37.64 | 23.67 | 4.42 | 2.85 | 3.05 | 3.97 | 0.43 | — |
Fulgent Genetics Inc. is a technology-based company specializing in genetic testing and precision medicine services. It operates a laboratory services business that provides technical laboratory testing and professional interpretation of results by licensed physicians, delivering clinically actionable diagnostic information to healthcare providers. This segment focuses on genomic diagnostics, including advanced platforms like FulgentExome for patient-centric exome analysis and Fulgent Pipeline Manager for processing genetic sequencing data. Complementing this, Fulgent Genetics Inc. maintains a therapeutic development business centered on oncology, developing drug candidates for various cancers using a proprietary nanoencapsulation and targeted therapy platform to enhance drug delivery, solubility, and efficacy. The company applies technologies such as bioinformatics, AI-driven digital pathology like Eziopath, and workflow optimization across its operations. Primarily serving the United States market, it supports physicians in areas like pathology, PCR testing, and anatomic pathology through CLIA- and CAP-accredited labs. Founded in 1996 and headquartered in El Monte, California, Fulgent Genetics Inc. integrates diagnostics and therapeutics to advance precision medicine in healthcare.